Spots Global Cancer Trial Database for A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions
Official Title: A Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics/ Pharmacodynamics of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions
Study ID: NCT04645797
Conditions
Interventions
Study Description
Brief Summary: A Phase 1 dose escalation study to evaluate APR003 in patients with advanced colorectal cancer (CRC) with malignant liver lesions
Detailed Description: APR003 is a small molecule TLR7 agonist that concentrates in the GI, and liver with limited systemic exposure. It is designed to increase the therapeutic window of a TLR7 agonist by minimizing the side-effects associated with generalized systemic immune activation and inflammation.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
AdventHealth Orlando, Orlando, Florida, United States
Carolina BioOncology Institute Cancer Research Clinic, Huntersville, North Carolina, United States
NEXT Oncology - Austin, Austin, Texas, United States
NEXT Oncology - San Antonio, San Antonio, Texas, United States
Contact Details
Name: Aaron Weitzman, MD
Affiliation: Apros Therapeutics, Inc
Role: STUDY_DIRECTOR
Name: Trinh Le
Affiliation: Apros Therapeutics, Inc
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
